Ginsenoside Rh7 Emerges as a Candidate Modulator of Postoperative Fibrinolysis After Hip Arthroplasty
Total hip arthroplasty THA reliably relieves end-stage hip disease, but the operation also triggers a biologic environment in which clot formation and clot breakdown can fall out of balance. In the hours after surgery, patients can move toward either bleeding or thrombosis if fibrinolysis becomes dysregulated. This study placed ginsenosides, the active constituents of Panax ginseng, into that perioperative setting and asked whether they might influence the molecular machinery that governs that balance.
The work combined network pharmacology, metabolomics, and cell-based validation. Nine active ginsenoside components were screened from database sources using ADME filtering, then mapped against fibrinolysis-related targets. From 351 component targets and 428 fibrinolysis-related targets, 65 key targets emerged at the intersection. The resulting target network was not a single-pathway story; it pointed to a broad signaling web that included AKT1, PTGS2, JUN, and related nodes tied to coagulation, platelet behavior, and inflammatory control.
One result stood out immediately. AKT1 sat at the center of the target network.
Coagulation, Platelet Activation, and Hypoxia Signaling Converged on Shared Targets
Protein-protein interaction analysis identified AKT1, PTGS2, JUN, and other proteins as core targets, while KEGG enrichment clustered the biology around complement and coagulation cascades, platelet activation, and the HIF-1 signaling pathway. Those pathways make physiologic sense in the perioperative period. Surgical trauma activates platelets, alters endothelial behavior, and shifts the balance between procoagulant and fibrinolytic forces; hypoxia-linked signaling can intensify that response by changing endothelial transcriptional programs and inflammatory tone.
Metabolomics added a second layer of evidence by identifying 292 differential metabolites after surgery. Several pathways were enriched, including arachidonic acid metabolism, purine metabolism, and glycerophospholipid metabolism. Those metabolic routes are tightly tied to membrane signaling, eicosanoid production, platelet activation, and vascular homeostasis. Arachidonic acid in particular is a biologically plausible bridge between tissue injury and coagulation because its downstream products influence platelet aggregation and vascular tone.
Exploratory correlation analysis linked adenosine, sphingosine, and arachidonic acid with changes in hemoglobin and platelet counts across the preoperative and postoperative samples. The finding does not prove causality, but it places the metabolite shifts in the same physiologic space as blood loss, platelet consumption, and endothelial response after surgery. In practice, postoperative fibrinolytic instability is rarely driven by one molecule alone; it reflects several systems moving at once.
Rh7, Rg3, Rh1, and F2 Showed Binding Potential Against Core Targets
Molecular docking extended the network model by pairing core proteins with specific ginsenosides. AKT1 was docked with ginsenoside Rh7, JUN with ginsenoside Rg3, PIK3CA with ginsenoside Rh1, and PTGS2 with ginsenoside F2. The binding affinities were described as favorable, supporting the idea that these compounds could interact with the signaling proteins identified in the pathway analysis.
The docking work matters because it offers a mechanistic explanation for why several ginsenosides might influence postoperative biology through different targets rather than a single receptor. In a setting like THA, where inflammation, endothelial activation, platelet signaling, and fibrinolysis change together, multi-target interaction is biologically plausible. Still, docking is a model, not a clinical endpoint. The real test is whether those interactions translate into measurable changes in endothelial behavior.
Endothelial Cell Experiments Pointed to a Fibrinolytic Shift With Rh7
That translational step came from in vitro validation in LPS-stimulated venous endothelial cells. Intervention with Rh7, Rg3, Rh1, and F2 significantly inhibited the mRNA and protein expression of AKT1, JUN, PIK3CA, and PTGS2, respectively. The Rh7 result was especially relevant because it went beyond target suppression and reached the fibrinolytic proteins themselves.
Rh7 significantly increased tissue-type plasminogen activator and reduced plasminogen activator inhibitor-1 in the stimulated endothelial model. That direction of effect favors fibrinolysis: t-PA promotes plasmin generation and clot breakdown, while PAI-1 restrains the same system. In other words, Rh7 shifted the endothelial balance toward a more pro-fibrinolytic state, at least under the experimental conditions used here.
The implication is narrow but important. If the endothelial response after THA is partly shaped by these pathways, Rh7 could be a candidate to temper the postoperative tilt away from fibrinolysis. The authors’ data position Rh7 as the most convincing of the tested compounds, because it linked target modulation with a functional readout in the fibrinolysis axis.
What the Combined Data Suggests for Perioperative Biology
The integrated network tied the ginsenosides to arachidonic acid metabolism, cGMP-PKG, cAMP, and sphingolipid signaling, with AKT1, PTGS2, JUN, and PIK3CA acting as common nodes. That pattern argues for a multi-pathway mechanism rather than a single linear drug effect. Endothelial cells do not respond to surgical stress in isolation; they integrate inflammatory signals, lipid mediators, platelet cues, and hypoxic changes into one surface response that can favor either hemostasis or fibrinolysis.
For perioperative medicine, the study offers a useful hypothesis rather than a practice change. The current data come from bioinformatic screening, one-patient paired metabolomics sampling, and cell culture validation. Those methods can generate a credible mechanistic framework, but they do not establish clinical efficacy, dosing, or safety in patients recovering from THA. The work also does not show whether Rh7 reaches relevant concentrations in humans after oral or perioperative administration, or whether it would alter bleeding and thrombosis risk in a real surgical cohort.
Even so, the pathophysiology is coherent. Surgical trauma perturbs the complement and coagulation systems, endothelial signaling, and platelet activity in parallel. A compound that nudges AKT1-linked signaling toward higher t-PA and lower PAI-1 fits the biology of a more balanced fibrinolytic response. The next question belongs in patients, not just in silico and in culture: whether that mechanism can be translated into a reproducible, safe perioperative strategy after total hip arthroplasty.